Martine Rothblatt has made no secret of her goal to move beyond the pharmaceutical business model that made her first foray into the biotech world — United Therapeutics Corp. (NASDAQ: UTHR) — a striking success.

This week, Rothblatt's ambitions earned her national TV time on CNBC's "Squawk Box", as she detailed her goal to transition the Silver Spring biotech, which now mostly develops and sells pulmonary hypertension drugs on the market, into the human organ manufacturing business.

Image: Martine Rothblatt discusses the potential of human organ manufacturing on CNBC this week.